The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Avapritinib for the treatment of AdvSM: Latest updates from the PATHFINDER study
|
During the European Hematology Association 2024 Hybrid Congress, Andreas Reiter shared 3-year follow up data from the phase II PATHFINDER study of avapritinib for the treatment of patients with advanced systemic mastocytosis (AdvSM). |
| Key learnings |
|
The overall response and complete response rates were numerically higher in the treatment-naïve setting (87% and 43%, respectively) vs in patients with ≥1 prior systemic therapy (66% and 21%, respectively). |
|
Median overall survival (OS) was not reached, regardless of AdvSM subtype or treatment history. |
|
The 36-month OS rate was 75%, with more favorable data for the treatment-naïve vs pre-treated cohort. |
|
No new safety concerns were identified during the follow up period, with most adverse events manageable with dose reduction or interruption. |
|
Data from PATHFINDER suggest avapritinib as a feasible treatment option in AdvSM, particularly in early lines of therapy. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content